{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:10:07Z","timestamp":1780103407778,"version":"3.54.0"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,1,11]],"date-time":"2011-01-11T00:00:00Z","timestamp":1294704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2011,8]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Diagnostic (validating cohort)<\/jats:p>\n                    <jats:p>Level of Evidence\u20031b<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Microscopic haematuria (\u00b5H) is frequently detected in elderly adults. The American Urological Association recommends the follow\u2010up of subjects with \u00b5H on bladder cancer. Whereas gross haematuria is considered an important sign of the presence of bladder cancer, the disease\u2010predictive value of \u00b5H is less clear.<\/jats:p>\n                    <jats:p>\n                      No association of \u00b5H with the development of bladder tumours in a prospective screening cohort of chemical workers was observed. The positive predictive value of \u00b5H for bladder cancer was as low as 1.2%. Haematuria interfered with NMP22 but not with cytology and UroVysion\n                      <jats:sup>TM<\/jats:sup>\n                      test results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\u2022\u2002To assess the positive predictive value (PPV) of microhaematuria (\u00b5H) and gross haematuria (GH) in bladder cancer screening and the influence of haematuria on tumour tests in a prospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\u2022\u2002From September 2003 to January 2010, 1323 men took part in an annual voluntary bladder cancer screening programme for chemical workers with former exposure to aromatic amines.<\/jats:p>\n                    <jats:p>\u2022\u2002In 5315 urine samples haematuria was determined with a dipstick, followed by a microscopic blood cell count in the sediment. Haematuria was categorized into traces, \u00b5H and GH.<\/jats:p>\n                    <jats:p>\u2022\u2002Urinary leukocytes and other factors were investigated as potential predictors of haematuria using a generalized estimating equation model for repeated urinalysis. The risk of haematuria for positive tumour tests was analysed correspondingly.<\/jats:p>\n                    <jats:p>\u2022\u2002The bladder cancer risk was estimated for the highest degree of haematuria occurring during the study with Poisson regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\u2022\u2002As of July 2010, 15 bladder tumours were detected in 14 participants.<\/jats:p>\n                    <jats:p>\u2022\u2002GH was found in four out of nine high\u2010grade tumours and associated with a rate ratio of 3.82, 95% confidence interval (CI) 0.50\u201329.15 for the development of bladder lesions.<\/jats:p>\n                    <jats:p>\u2022\u2002The PPV of GH was 11.4%, but only 1.2% for \u00b5H. \u00b5H occurred in 18.8% of urine samples and was not associated with bladder cancer [rate ratio (RR) 0.72, 95% CI 0.11\u20134.78].<\/jats:p>\n                    <jats:p>\u2022\u2002Abundant urinary leukocytes were associated with \u00b5H [odds ratio (OR) 8.34, 95% CI 2.26\u201330.69] and even stronger with GH (OR 22.25, 95% CI 6.42\u201377.06).<\/jats:p>\n                    <jats:p>\n                      \u2022\u2002Haematuria and leukocytes influenced NMP22 positivity (\u00b5H: OR 1.63, 95% CI 1.06\u20132.51, abundant leukocytes: OR 8.90, 95% CI 1.58\u201350.16), but not test results for urine cytology and UroVysion\n                      <jats:sup>TM<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\u2022\u2002While the PPV of \u00b5H for bladder cancer was low, there was a strong influence of haematuria and leukocytes on the protein\u2010based tumour test NMP22\u00ae.<\/jats:p>\n                    <jats:p>\u2022\u2002Erythrocytes and leukocytes should be determined at least semi\u2010quantitatively for the interpretation of positive NMP22 test results.<\/jats:p>\n                    <jats:p>\n                      \u2022\u2002In addition, a panel of tumour tests that includes methods not affected by the presence of erythrocytes or leukocytes such as cytology and UroVysion\n                      <jats:sup>TM<\/jats:sup>\n                      would improve bladder cancer screening.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2010.09971.x","type":"journal-article","created":{"date-parts":[[2011,1,11]],"date-time":"2011-01-11T13:52:43Z","timestamp":1294753963000},"page":"546-552","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines"],"prefix":"10.1111","volume":"108","author":[{"given":"Beate","family":"Pesch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nasterlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedhelm","family":"Eberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Bonberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Taeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Feil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Johnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katta","family":"Ickstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Kluckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Wellh\u00e4u\u00dfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnllf","family":"Stenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Br\u00fcning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the UroScreen Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,11]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043764-199009000-00016"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)00919-0"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)00920-7"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22224"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07596.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.7.810"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta10180"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/106689690501300203"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.101.2629.519"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-10724-9"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-007-0223-2"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.299.6706.1010"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.02.142"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018453104303"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq214"},{"key":"e_1_2_8_17_2","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1158\/1055-9965.EPI-07-2619","article-title":"Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum","volume":"16","author":"Brenner DE","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1191\/1740774506cn130oa"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22084"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/29.2.238"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1078\/1438-4639-00188"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08360.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)69084-0"}],"updated-by":[{"DOI":"10.1111\/j.1464-410x.2011.10636_3.x","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T00:00:00Z","timestamp":1315872000000}}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2010.09971.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2010.09971.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:42:28Z","timestamp":1761756148000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2010.09971.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,11]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["10.1111\/j.1464-410X.2010.09971.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2010.09971.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,11]]},"assertion":[{"value":"2011-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}